PPA
NRIX icon

Parametric Portfolio Associates’s Nurix Therapeutics NRIX Stock Holding History

Parametric Portfolio Associates’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,847
Closed -$285K – 3737
2021
Q4 		$285K Sell
9,847
-1,560
-14% -$47.3K ﹤0.01% 3301
2021
Q3 		$342K Sell
11,407
-1,975
-15% -$60.9K ﹤0.01% 3249
2021
Q2 		$355K Buy
13,382
+6,368
+91% +$187K ﹤0.01% 3210
2021
Q1 		$218K Buy
+7,014
New +$265K ﹤0.01% 3843

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parametric Portfolio Associates's NRIX Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 9,847 shares — an estimated $285K sold.

Parametric Portfolio Associates first reported a position in NRIX in Q1 2021 and held it in 4 quarters. The position peaked at $355K in Q2 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 9,847 Nurix Therapeutics shares in Q1 2022, an estimated $285K.
  • Parametric Portfolio Associates first reported a position in Nurix Therapeutics in Q1 2021 and held it in 4 quarters.
  • Parametric Portfolio Associates's Nurix Therapeutics position peaked at $355K in Q2 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.